Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure

@article{GarnockJones2013BrentuximabVA,
  title={Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure},
  author={Karly P. Garnock-Jones},
  journal={Drugs},
  year={2013},
  volume={73},
  pages={371-381}
}
Brentuximab vedotin (ADCETRIS®) is an antibody-drug conjugate that is specifically targeted against CD30-positive cancer cells such as those in Hodgkin lymphoma or systemic anaplastic large cell lymphoma (ALCL). Intravenous brentuximab vedotin was associated with an overall objective response rate (primary endpoint) of 75 % in 102 patients with Hodgkin lymphoma who had relapsed after high-dose chemotherapy and autologous haematopoietic stem cell transplantation, in a noncomparative, multicentre… CONTINUE READING
11 Citations
16 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Long-term survival analyses of an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma [abstract

  • R Chen, AK Gopal, SE Smith
  • 2012
Highly Influential
20 Excerpts

Long-term remissions observed in an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma [abstract

  • B Pro, R Advani, P Brice
  • 2012
Highly Influential
9 Excerpts

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: a phase 2 study update [abstract

  • RH Advani, AR Shustov, P Brice
  • 2011
Highly Influential
9 Excerpts

Recent advances in the pathobiology of Hodgkin’s lymphoma: Potential impact on diagnostic, predictive, and therapeutic strategies

  • D. Banerjee
  • Adv Hematol
  • 2011
Highly Influential
2 Excerpts

Long - term survival analyses of an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma [ abstract no . 3689 ]

  • R Chen, AK Gopal, SE Smith
  • Blood
  • 2012

Brentuximab vedotin ( SGN35 ) in patients with relapsed or refractory systemic anaplastic large cell lymphoma : a phase 2 study update [ abstract no . 443 ]

  • RH Advani, AR Shustov, P Brice
  • Blood
  • 2011

Similar Papers

Loading similar papers…